Menu Search
Equities

Sanofi SA

SAN:PAR

Sanofi SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)90.87
  • Today's Change0.07 / 0.08%
  • Shares traded1.33m
  • 1 Year change+6.48%
  • Beta0.4932
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy6
Outperform11
Hold5
Sell2
Strong Sell0

Share price forecast in EUR

The 21 analysts offering 12 month price targets for Sanofi SA have a median target of 113.00, with a high estimate of 126.00 and a low estimate of 90.00. The median estimate represents a 24.45% increase from the last price of 90.80.
High38.8%126.00
Med24.4%113.00
Low-0.9%90.00

Dividends in EUR

In 2023, Sanofi SA reported a dividend of 3.76 EUR, which represents a 5.62% increase over last year. The 18 analysts covering the company expect dividends of 3.84 EUR for the upcoming fiscal year, an increase of 2.21%.
Div growth (TTM)5.62%
More ▼

Earnings history & estimates in EUR

On Oct 25, 2024, Sanofi SA reported 3rd quarter 2024 earnings of 2.86 per share. This result exceeded the 2.47 consensus of the 8 analysts covering the company and exceeded last year's 3rd quarter results by 12.16%.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate+8.71%
Sanofi SA reported annual 2023 earnings of 8.11 per share on Feb 01, 2024.
Average growth rate+8.47%
More ▼

Revenue history & estimates in EUR

Sanofi had 3rd quarter 2024 revenues of 13.44bn. This bettered the 12.83bn consensus of the 9 analysts covering the company. This was 31.46% above the prior year's 3rd quarter results.
Average growth rate+3.71%
Sanofi had revenues for the full year 2023 of 43.07bn. This was 0.17% above the prior year's results.
Average growth rate+4.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.